Ownership and insider activity for Dare Bioscience, Inc. (DARE): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis.
Price
| Price | $0.75 |
| Market Cap | $11M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-30 | Grossman Jessica D. | A-Award | 26,066 | |
| 2026-06-30 | Kelley Susan L. | A-Award | 23,696 | |
| 2026-06-30 | Matz Gregory W | A-Award | 30,805 | |
| 2026-06-30 | RASTETTER WILLIAM H | A-Award | 38,862 | |
| 2026-06-30 | Steele Robin Joan | A-Award | 26,540 | |
| 2026-06-11 | RASTETTER WILLIAM H | A-Award | 10,000 | $20K |
| 2026-06-11 | Kelley Susan L. | A-Award | 10,000 | $20K |
| 2026-06-11 | Steele Robin Joan | A-Award | 10,000 | $20K |
| 2026-06-11 | Matz Gregory W | A-Award | 10,000 | $20K |
| 2026-06-11 | Grossman Jessica D. | A-Award | 10,000 | $20K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $35.0M | $7.6M | $6.8M | $4.8M | $4.7M | $51.7M | $34.7M | $10.5M | $15.7M | $24.7M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | $284206 | $31037 | $555210 | $460168 | $1.1M | $1.7M | $949211 | $229982 | $573061 |
| Inventory | -$1.8M | $311571 | -$402.7M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $36.8M | $8.3M | $7.2M | $6.4M | $7.0M | $55.3M | $43.0M | $17.5M | $18.4M | $27.1M |
| Property, Plant & Equipment | $668000 | 0 | $9396 | $551811 | $277480 | $242714 | $522833 | $2.0M | $2.5M | $4.4M |
| Goodwill | 0 | $5.2M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $37.7M | $14.3M | $7.8M | $7.4M | $7.6M | $55.8M | $43.8M | $21.3M | $22.1M | $32.5M |
| Accounts Payable | $1.4M | $308219 | $459705 | $1.1M | $1.0M | $2.1M | $2.0M | $3.4M | $1.5M | $1.2M |
| Short-term Debt | $8.4M | 0 | 0 | 0 | $367285 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $16.9M | $966653 | $1.1M | $5.6M | $7.7M | $16.1M | $31.6M | $20.5M | $21.6M | $23.7M |
| Long-term Debt | $4.4M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $24.6M | $967045 | $1.1M | $7.0M | $8.7M | $17.1M | $32.7M | $26.3M | $28.1M | $29.6M |
| Retained Earnings | -$200.7M | -$12.2M | -$29.0M | -$44.0M | -$71.4M | -$110.1M | -$141.1M | -$171.2M | -$175.3M | -$188.7M |
| Total Equity | $13.1M | $13.3M | $6.7M | $440826 | -$1.2M | $38.8M | $11.1M | -$5.0M | -$6.0M | $2.8M |
| Total Debt | $12.8M | 0 | 0 | $800452 | $756841 | $270546 | $488737 | $1.4M | $1.3M | $2.7M |
| Net Debt | -$22.1M | -$7.6M | -$6.8M | -$4.0M | -$3.9M | -$51.4M | -$34.2M | -$9.1M | -$14.4M | -$22.1M |
| Working Capital | $19.9M | $7.4M | $6.1M | $831526 | -$676689 | $39.2M | $11.4M | -$2.9M | -$3.2M | $3.4M |
Financial Health
| Debt / Equity | -12.08 |
| Current Ratio | 0.99 |
Profitability
| Return on Equity | -748.08% |
| Return on Invested Capital | -179.10% |
| Return on Assets | -49.12% |
| Gross Margin | -89.45% |
| Operating Margin | -813.38% |
| Net Margin | -804.37% |
Related companies: ADTX · AIMD · ANL · ASBP · ATHA · CTXR · FBLG
Explore sector: Healthcare · Biotechnology
More sections of DARE: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks